HOXB13, a crucial B-class homeobox transcription factor, plays a significant role in developmental gene networks and has emerged as a pivotal regulator in human cancer. While essential for embryonic patterning and androgen-dependent organogenesis, HOXB13’s expression is often altered by various mechanisms such as epigenetic modifications, mutations, and post-translational events, influencing tumor development, progression, and response to therapy. Interestingly, HOXB13 acts as both an oncogene and a tumor suppressor across different cancer types, depending on factors like tissue context, mutational status, and interacting partners.
The dysregulation of HOXB13 at the transcriptional level is a primary mechanism in cancer. For instance, in prostate cancer, the binding of BRD4 to enhancer elements triggers HOXB13 overexpression, promoting cell-cycle progression and nucleotide-metabolism gene activation. Conversely, in endometrial carcinoma and glioma, the silencing of HOXB13 through H3K27me3 or HDAC4 recruitment inhibits proliferation. Additionally, CpG methylation status further influences HOXB13 expression, with hypermethylation silencing the gene in certain cancers while hypomethylation amplifies its transcription in others.
Post-transcriptional modifications, such as m6A editing of HOXB13 mRNA, play a crucial role in cancer biology. Processes like FTO-mediated demethylation of the 3′ UTR can impact mRNA stability and invasion in specific cancers. Circular RNAs and long non-coding RNAs also modulate HOXB13 expression by sponging microRNAs, leading to altered protein levels. Post-translational modifications, including acetylation and phosphorylation, further regulate HOXB13’s stability and activity, ultimately determining its function as either a tumor promoter or suppressor.
HOXB13’s interactions with other proteins are intricate and significantly influence its role in cancer. For example, in prostate epithelium, HOXB13 forms complexes with MEIS1 to regulate androgen receptor signaling and tumor suppressor activity. Mutations disrupting these interactions can lead to oncogenic processes. Furthermore, HOXB13’s direct interaction with various transcription factors and signaling pathways influences key processes like proliferation, invasion, and angiogenesis in different cancer types, highlighting its multifaceted role in tumor biology.
Clinically, HOXB13 has emerged as a valuable biomarker for cancer diagnosis and prognosis. Immunohistochemistry for HOXB13 aids in distinguishing between different tumor types, and its expression levels have prognostic value in various cancers. Moreover, targeting HOXB13 therapeutically shows promise, with inhibitors of key pathways involved in HOXB13 dysregulation being explored for cancer treatment. Understanding the geographic and ethnic variations in HOXB13-related mutations is also crucial for personalized clinical strategies and risk prediction across diverse populations.
Key Takeaways:
– HOXB13 acts as a context-dependent regulator in cancer biology, serving as both an oncogene and tumor suppressor.
– Dysregulation of HOXB13 at multiple levels, including transcriptional, post-transcriptional, and post-translational, influences its function in cancer.
– Interactions with other proteins and pathways significantly impact HOXB13’s role in tumor progression and therapy response.
– HOXB13 has clinical implications as a biomarker for cancer diagnosis, prognosis, and therapeutic targeting.
Tags: upstream, transcriptomics
Read more on news-medical.net